{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:18:51Z","timestamp":1741238331539,"version":"3.38.0"},"reference-count":59,"publisher":"JLE","issue":"3","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.nephro.2007.03.002","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T11:35:04Z","timestamp":1178796904000},"page":"79-88","source":"Crossref","is-referenced-by-count":0,"title":["Quelle bith\u00e9rapie antihypertensive optimale pour\u00a0les\u00a0patients n\u00e9phrologiques?"],"prefix":"10.1684","volume":"3","author":[{"given":"Jean-Fran\u00e7ois","family":"Bonne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Shahapuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Oprisiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Temmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"issue":"6","key":"10.1016\/j.nephro.2007.03.002_bib1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ndt\/gfh813","article-title":"Chronic kidney disease as cause of cardiovascular morbidity and mortality","volume":"20","author":"Vanholder","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nephro.2007.03.002_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin converting enzyme inhibitor on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.nephro.2007.03.002_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.nephro.2007.03.002_bib4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"9502","key":"10.1016\/j.nephro.2007.03.002_bib5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin\u2013angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib6","first-page":"897","article-title":"Correspondence on Juan Casas Meta-analysis","volume":"367","author":"Casas","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(06)69172-1","article-title":"Overview of randomised trials of ACE inhibitors","volume":"368","author":"Remuzzi","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.nephro.2007.03.002_bib8","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"issue":"9395","key":"10.1016\/j.nephro.2007.03.002_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.nephro.2007.03.002_bib10","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.2174\/138161205774424726","article-title":"The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection","volume":"11","author":"Magy","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nephro.2007.03.002_bib11","first-page":"410","article-title":"Randomized double blinded trial of enalapril versus hydrochlorothiazide on GFR in diabetic nephropathy","volume":"22","author":"Walker","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2007.03.002_bib12","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to Doxazosin vs Chlorthalidone","volume":"283","year":"2000","journal-title":"Jama"},{"doi-asserted-by":"crossref","unstructured":"Presne C, et al. Hypertension associ\u00e9e aux st\u00e9noses de l'art\u00e8re r\u00e9nale et aux atteintes r\u00e9nales parenchymateuses. Encycl Med Chir Elsevier, 2006.","key":"10.1016\/j.nephro.2007.03.002_bib13","DOI":"10.1016\/S1166-4568(06)21134-3"},{"issue":"7160","key":"10.1016\/j.nephro.2007.03.002_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.nephro.2007.03.002_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.nephro.2007.03.002_bib16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"Jama"},{"issue":"19","key":"10.1016\/j.nephro.2007.03.002_bib17","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.nephro.2007.03.002_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nephro.2007.03.002_bib19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.nephro.2007.03.002_bib21","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.nephro.2007.03.002_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.nephro.2007.03.002_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.nephro.2007.03.002_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2007.03.002_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/01.HYP.23.1.114","article-title":"Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension","volume":"23","author":"Wenzel","year":"1994","journal-title":"Hypertension"},{"issue":"9463","key":"10.1016\/j.nephro.2007.03.002_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.nephro.2007.03.002_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.7326\/0003-4819-135-2-200107170-00015","article-title":"The effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials","volume":"135","author":"Schrier","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.nephro.2007.03.002_bib28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study","volume":"22","author":"Marre","year":"2004","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.nephro.2007.03.002_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int."},{"issue":"9352","key":"10.1016\/j.nephro.2007.03.002_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/ki.2005.4496234","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: new therapeutic world beyond blood pressure reduction","volume":"68","author":"Nakao","year":"2005","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.nephro.2007.03.002_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.nephro.2007.03.002_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.nephro.2007.03.002_bib34","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: evolving perspectives","volume":"18","author":"Epstein","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.nephro.2007.03.002_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","volume":"69","author":"Suissa","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.nephro.2007.03.002_bib36","first-page":"12","article-title":"Kidneys and fluids in pressure regulation","volume":"19","author":"Guyton","year":"1992","journal-title":"Small volume but large pressure changes. hypertension"},{"issue":"5","key":"10.1016\/j.nephro.2007.03.002_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"7201","key":"10.1016\/j.nephro.2007.03.002_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long-term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.nephro.2007.03.002_bib39","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.nephro.2007.03.002_bib40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.nephro.2007.03.002_bib41","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7470","key":"10.1016\/j.nephro.2007.03.002_bib42","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.nephro.2007.03.002_bib43","series-title":"Hypertension art\u00e9rielle \u2013 Chapitre I du Trait\u00e9 de M\u00e9decine Interne \u00e9dit\u00e9 par Godeau\u2013Piette","first-page":"1","author":"Fournier","year":"2004"},{"issue":"9446","key":"10.1016\/j.nephro.2007.03.002_bib44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"9496","key":"10.1016\/j.nephro.2007.03.002_bib45","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9426","key":"10.1016\/j.nephro.2007.03.002_bib47","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.nephro.2007.03.002_bib49","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2007.03.002_bib50","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2007.03.002_bib51","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.nephro.2007.03.002_bib52","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.nephro.2007.03.002_bib53","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.hjh.0000194114.12228.16","article-title":"Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds","volume":"23","author":"Volpe","year":"2005","journal-title":"J. Hypertens."},{"issue":"7477","key":"10.1016\/j.nephro.2007.03.002_bib54","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.329.7477.1248","article-title":"Angiotensin receptor blockers and myocardial infarction","volume":"329","author":"Verma","year":"2004","journal-title":"BMJ"},{"issue":"9535","key":"10.1016\/j.nephro.2007.03.002_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomized trial of a perindopril\u2013based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2007.03.002_bib57","first-page":"710","article-title":"Post-stroke Antihypertensive Study","volume":"108","year":"1995","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"6","key":"10.1016\/j.nephro.2007.03.002_bib58","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.nephro.2007.03.002_bib59","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJM199912093412402","article-title":"The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group","volume":"341","author":"Poldermans","year":"1999","journal-title":"N. Engl. J. Med."}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725507000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725507000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2007.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:51:41Z","timestamp":1741182701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725507000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1769725507000454"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2007.03.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}